Business Context and Reporting Period
Company: Can-Fite Biopharma Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Date: March 26, 2026
Context: The filing serves to distribute a press release announcing the company's 2025 financial results and ongoing clinical progress.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are referenced as being contained within the attached press release (Exhibit 99.1) but are not present in the body of this Form 6-K.
Material Changes and Clinical Progress
- Clinical Data: The company reported positive data in a Phase 2a study for pancreatic cancer.
- Patient Outcome: Highlighted a case of 9 years cancer-free survival in a liver cancer patient.
- Financials: The filing references the release of 2025 financial results but does not detail specific year-over-year changes in the text provided.
Guidance, Outlook, and Risks
The filing text does not provide specific forward-looking guidance, management commentary on future financial performance, or a detailed list of risks and contingencies. The primary focus of the text is the dissemination of the press release regarding clinical milestones and the 2025 financial summary.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific 2025 revenue, net loss, and cash burn figures.
- Verify the full dataset and statistical significance of the Phase 2a pancreatic cancer results.
- Confirm the current cash runway and liquidity position as of the end of 2025.
- Assess the timeline for upcoming regulatory filings or trial expansions based on the reported clinical data.